David Medin has 30 years experience in semiconductors, software and systems in consumer and commercial sectors. He has founded and secured funding for multiple technology startups and has held CEO and CTO positions at private and public companies. Prior companies include NVIDIA, TVIA, Spatial Photonics, Innovision, Tymphany, Maxcell Telecom.
Mr. Medin is an inventor on over 34 patents and applications with issued patents in 12 countries. Mr. Medin has a B.S.E.E. from University of Maryland.
Mr. Matus has 15 years of experience working with high technology companies and early stage startups in technology development and pathfinding in MEMS, CMOS and silicon technologies. Prior to SnapDNA, Mr. Matus developed a process to make bulk materials based on silicon nanostructures, which can be used for megawatt scale energy harvesting from industrial waste heat at Alphabet Energy. Prior to Alphabet, Mr. Matus developed micromirror and MEMS on CMOS fabrication and packaging technologies for Light Blue Optics, Spatial Photonics, MicroAssembly Technologies, Adriatic Research Institute and Onix Microsystems for diverse applications including fiber optic switching, freespace communication and high volume portable projection displays. Mr. Matus has 6 issued patents, and 17 applications in progress. Mr. Matus received his B.S. in Materials Science and Engineering from the University of California, Berkeley.
Veronica De Guzman has 13 years experience in formulation and pilot-scale manufacturing process development for biopharmaceutical companies such as Inhale (Nektar) Therapeutic Systems and MAP Pharmaceuticals (Allergan). She also has over 10 years experience in single molecule DNA analysis. Dr. De Guzman received her B.S. in Biological Sciences from University of California, Davis, and her Ph. D. in Biochemistry from University of California, Santa Cruz.
Dr. Lehrman, has more than 25 years experience leading analytical and formulation in the biotechnology and pharmaceutical industries. These programs improved the therapeutic value of proteins, small molecules, and nucleic acid-based clinical candidates at Elan, Nektar, NeXstar, and Pfizer (Upjohn). He has also successfully developed novel formulations and analytical methodologies to support clinical development. As an industry consultant, Dr. Lehrman has managed drug development operations for client companies, and has served as an expert witness in contract violation and patent infringement cases.
Dr. Lehrman has over 80 publications and 7 patents, is an Adjunct Professor at the University of Kansas, School of Pharmacy and is a frequent guest lecturer. In addition, he has been an active organizer and contributor of mini symposia and group lecture series. Dr. Lehrman received his B.Sc. in Chemistry from McGill University, Montreal, Canada, and Ph.D. in Pharmaceutical Chemistry from the University of Wisconsin-Madison.